Journal of Clinical Oncology
Articles in this Issue
Brain metastases in HER2- positive metastatic gastrointestinal cancers: Incidence, timing, and implications for brain surveillance.
e16001 Background: Brain metastases (BM) are considered rare in gastrointestinal (GI) malignancies, and routine brain imag...
A prospective clinical and dosimetric study on the feasibility and adaptability of MR-Linac in the treatment of cervical cancer: Initial experience from a tertiary institution.
e17527 Background: Cervical cancer is a leading cause of cancer burden globally, with a disproportionate burden in LMICs l...
Post-treatment ctDNA monitoring using a tumor-informed whole-genome sequencing-based assay in homologous recombination–proficient ovarian cancer.
5592 Background: Ovarian cancer (OC) has high mortality due to advanced stage at diagnosis and frequent, incurable recurre...
Preclinical efficacy and brain uptake of an insulin-mediated nanoparticle co-delivering trastuzumab and pertuzumab (AxS007) in HER2+ breast cancer brain metastasis models.
2027 Background: Anti-HER2 antibodies are standard therapies for metastatic HER2+ breast cancer but demonstrate limited in...
Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition.
2629 Background: CTX-8371 is a novel bispecific antibody targeting both programmed cell death 1 (PD-1) and programmed cell...
Clinicopathologic and molecular features of Krukenberg tumors from gastric cancer (GC): A single-institution experience.
4043 Background: Krukenberg tumors (KTs), ovarian metastases most commonly arising from gastric adenocarcinoma, represent...
Tumor microenvironment modulation by losartan in advanced gallbladder cancer (GBC): Results and genomic correlates from the phase 2 LAST study.
4154 Background: Advanced gallbladder cancer (GBC) carries a dismal prognosis, with a real-world median overall survival (...
YOCAS yoga, mood disturbance, and insomnia: A URCC NCORP RB nationwide, phase III, randomized, controlled trial with cancer survivors.
12004 Background: Mood disturbance (MoD) and insomnia are two of the most pervasive and troubling side effects experienced...
Twenty-five years of the IMPACT men’s health study: Survivorship, health behaviors, and social determinants of health among uninsured and underrepresented prostate cancer patients.
e13586 Background: The UCLA Men’s Health Study (MHS) was initiated 25 years ago to address critical gaps in prostate cance...
Achieving epidemiologically representative enrollment and social determinants of health in the phase III evERA Breast Cancer study (NCT05306340).
1572 Background: Clinical trials have historically under-enrolled patients (pts) from racial and ethnic minority groups, r...
Peak inflammatory stress versus baseline neutrophil-to-lymphocyte ratio (NLR) for prediction of in-hospital mortality in critically ill glioblastoma patients: MIMIC-IV cohort analysis.
e14103 Background: Systemic inflammation is a recognized driver of disease progression in Glioblastoma (GBM). While the Ne...
Longitudinal safety of lisocabtagene maraleucel (liso-cel) in patients (pt) with second-line or later (2L+) large B-cell lymphoma (LBCL).
7031 Background: Liso-cel has shown favorable efficacy and a manageable, consistent safety profile across B-cell malignanc...
Embedding germline genetic testing into African oncology care: Early results from the Genetic Cancer Families (GenCAF) program.
10572 Background: Breast cancer outcomes in sub-Saharan Africa are marked by early onset, advanced stage at diagnosis, and...
Clinical validation of ultra-sensitive WGS-based MRD detection in head and neck squamous cell carcinoma: Results from MONSTAR-SCREEN-3.
6066 Background: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has shown promise across v...
Safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activities of FL115, a novel IL-15 superagonist, from the first-in-human study in patients with locally advanced/metastatic solid tumors.
3154 Background: FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein, in which Fbody is a single-chain Fc designed to...
Social determinants of health and long-term outcomes in prostate cancer: Mortality, survival, and comorbidity risks in a propensity score–matched federated database analysis.
12119 Background: Social determinants of health (SDOH) such as housing instability, food insecurity, and low income are kn...
Comparative outcomes of leukapheresis and pharmacologic cytoreduction in hyperleukocytosis.
e18554 Background: Hyperleukocytosis, defined as a white blood cell (WBC) count ≥100 × 10⁹/L, is a hematologic emergency i...
Disrupting the microbiome, disrupting immunity: Antibiotic exposure and survival outcomes with immune checkpoint inhibitors—A systematic review.
e23430 Background: The gut microbiome plays a critical role in shaping antitumor immunity and response to immune checkpoin...
Risk stratification in systemic AL amyloidosis with cardiac involvement using a multiparametric echocardiography score.
e24024 Background: Mortality in AL amyloidosis is chiefly driven by the degree of cardiac involvement, known as light chai...
Sotorasib vs adagrasib in the 2L+ setting: Outcomes in a large, multi-institutional, real-world database of KRAS-G12C mutated mNSCLC.
8608 Background: KRAS-G12C mutations are found in ~12% of mNSCLC. KRAS-G12C inhibitors sotorasib and adagrasib are approve...
Quantifying equol-producing and beta-glucuronidating gut bacteria in breast cancer using 16S rDNA sequencing methods.
10601 Background: Gut bacteria with hormone-modulating potential may influence breast cancer (BC) risk: Equol-producing ba...
Spatial immune architecture as a predictor of response to neoadjuvant chemoradiotherapy in rectal cancer.
e15739 Background: Response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer is highly variable,...
Comparison of cardiovascular outcomes among solid tumor ADCs: A tumor-agnostic observational study.
e15208 Background: Antibody-drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic payloads to selectively de...
Scaling deep learning for neuro-oncology: Knowledge-distilled EfficientNetB0 powered MRI classification of brain tumors with international expert validation.
2018 Background: Accurate classification of brain tumors on magnetic resonance imaging (MRI) is critical for timely diagno...
Cadonilimab in combination with ivonescimab and chemotherapy as first-line (1L) therapy in patients with advanced gastric (G) or gastroesophageal junction adenocarcinoma (GEJA): Updated results from an open-label phase II trial.
4048 Background: Cadonilimab (AK104), an anti-PD-1/CTLA-4 bispecific antibody, plus chemotherapy significantly improved OS...